Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival

Immunology

Volumn 92, Issue 3, 1997, Pages 334-339

  Blackstock, R ^a   Casadevall, A ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYSACCHARIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CELL SURVIVAL; CELLULAR IMMUNITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DELAYED HYPERSENSITIVITY; GRANULOMATOUS INFLAMMATION; IMMUNE RESPONSE; INFECTION RISK; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

EID: 0030700722     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1997.00357.x     Document Type: Article

References (34)

1. GRAYBILL J.R. & ALFORD R.H. (1974) Cell-mediated immunity in cryptococcosis. Cell Immunol 14, 12.
2. MURPHY J.W. (1996) Cell-mediated immunity. In: The Mycota Volume VII, Animal and Human Realtionships (eds J. D. Miller & D. H. Howard), Vol. 1, p. 67. Springer-Verlag, New York.
3. HUFFNAGLE G.B., LIPSCOMB M.F., LOVCHIK J.A., HOAG K.A. & STREET N.E. (1994) The role of CD4 (+) and CD8 (+) T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 55, 35.
4. HUFFNAGLE G.B., TOEWS G.B., BURDICK M.D. et al. (1996) Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neuformans. J Immunol 157, 4529.
5. LIPSCOMB M.F. (1996) Cellular basis for protection against pulmonary cryptococcal infections. In: Proceedings of the 3rd International Conference on Cryptococcus and Cryptococcosis 1996 (eds F. Dromer, B. Dupont & K. J. Kwon-Chung), p.73. Institut Pasteur, Paris.
6. TSUKADA H., KAWAMURA I., ARAKAWA M., NOMOTO K. & MITSUYAMA M. (1991) Dissociated development of T-cells mediating delayed-type hypersensitivity and protective T-cells against Listeria monocytogenes and their functional difference in lymphokine production. Infect Immun 59, 3589.
7. HILL J.O. (1992) CD4+ T-cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J Exp Med 175, 1685.
8. GOLDMAN D., LEE S.C. & CASADEVALL A. (1994) Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 62, 4755.
9. MORGAN M.A., BLACKSTOCK R., BULMER G.S. & HALL N.K. (1983) Modification of macrophage phagocytosis in murine cryptococcosis. Infect Immun 40, 493.
10. BLACKSTOCK R., ZEMBALA M. & ASHERSON G.L. (1991) Functional equivalence of cryptococcal and haptene-specific T-suppressor factor (TsF). II. Monoclonal anti-cryptococcal TsF inhibits both phagocytosis by a subset of macrophages and transfer of contact sensitivity. Cell Immunol 136, 448.
11. BLACKSTOCK R., ZEMBALA M. & ASHERSON G.L. (1991) Functional equivalence of cryptococcal and haptene-specific T-suppressor factor (TsF). I. Picryl and oxazolone-specific TsF, which inhibit transfer of contact sensitivity, also inhibit phagocytosis by a subset of macrophages. Cell Immunol 136, 435.
12. BRITZ J.S., ASKENASE P.W., PTAK W., STEINMAN R.M. & GERSHON R.K. (1982) Specialized antigen-presenting cells, splenic dendritic cells and peritoneal-exudate cells induced by mycobacteria activate effector T cells that are resistant to suppression. J Exp Med 155, 1344.
13. BLACKSTOCK R. & HERNANDEZ N.C. (1988) Inhibition of phagocytosis in cryptococcosis: phenotypic analysis of the suppressor cell. Cell Immunol 114, 174.
14. ROBINSON B.E., HALL N.K., BULMER G.S. & BLACKSTOCK R. (1982) Suppression of responses to cryptococcal antigen in cryptococcosis. Mycopathol 80, 157.
15. BULMER G.S., SANS M.D. & GUNN C.M. (1967) Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol 94, 1475.
16. HALL N.K., MALUF K.C. & BLACKSTOCK R. (1984) Functional testing and chemical composition of cryptococcal extracts. Sabouraudia 22, 439.
17. BENNETT J.E. (1981) Cryptococcal skin test antigen: preparation variables and characterization. Infect Immun 32, 373.
18. BLACKSTOCK R., MCCORMACK J.M. & HALL N.K. (1987) Induction of a macrophage suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunological tolerance. Infect Immun 55, 233.
19. NOWAK T.P. & BARONDES S.H. (1975) Agglutinin from Limulus polyphemus. Purification with formalinized horse erythrocytes as the affinity adsorbent. Biochem Biophy Acta 393, 115.
20. BLACKSTOCK R., HALL N.K. & HERNANDEZ N.C. (1989) Characterization of a suppressor factor that regulates phagocytosis by macrophages in murine cryptococcosis. Infect Immun 57, 1773.
21. CASADEVALL A., MUKHERJEE J. & SCHARFF M.D. (1992) Monoclonal antibody based ELISA for cryptococcal polysaccharide. J Immunol Methods 154, 27.
22. CASADEVALL A., MUKHERJEE J., DEVI S.J.N., SCHNEERSON R., ROBBINS J.B. & SCHARFF M.D. (1992) Antibodies elicited by a Cryptococcus neoformans tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 165, 1086.
23. MUKHERJEE J., SCHARFF M.D. & CASADEVALL A. (1992) Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 60, 4534.
24. MURPHY J.W. (1989) Clearance of Cryptococcus neoformans from immunologically suppressed mice. Infect Immun 57, 1946.
25. BLACKSTOCK R. & HALL N.K. (1984) Nonspecific immune suppression by Cryptococcus neoformans infection. Mycopathol 86, 35.
26. GOLDMAN D.L., LEE S.C. & CASADEVALL A. (1995) Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun 63, 3448.
27. DONG Z.M. & MURPHY J.W. (1995) Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun 63, 770.
28. MURPHY J.W., MOSLEY R.L., CHERNIAK R., REYES G., KOZEL T.R. & REISS E. (1988) Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun 56, 424.
29. ASHERSON G.L., COLIZZI V. & ZEMBALA M. (1986) An overview of T-suppressor cell circuits. Annu Rev Immunol 4, 37.
30. FASLER S., AVERSA G., TERR A., THESTRUP-PEDERSEN K., DEVRIES J.E. & YSSEL H. (1995) Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13. J Immunol 155, 4199.
31. VECCHIARELLI A., RETINI C., MONARI C., TASCINI C., BISTONI F. & KOZEL T. (1996) Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 64, 2846.
32. KAWAKAMI K., TOHYAMA M., QIFENG X. & SAITO A. (1997) Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12. Infect Immun 65, 1307.
33. BULMER G.S. & SANS M.D. (1968) Cryptococcus neoformans. III. Inhibition of phagocytosis. J Bacteriol 95, 5.
34. MURPHY J.W. & MOORHEAD J.W. (1982) Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J Immunol 128, 276.